At Myka Labs, our mission is to help millions of patients with pancreatic cancer and other challenging conditions live longer, healthier lives. Our Conflux(TM) platform combines advanced artificial intelligence with miniaturized ultrasound sensors to map the internal anatomy around a patient’s malignancy—in real time and with exquisite accuracy. With the benefit of Conflux’s sophisticated mapping capabilities, care teams are enabled to carry out treatments less invasively, with potentially enormous benefits for patients. Myka’s first Conflux-based product, the Connect-EA for a rare pediatric condition, is currently in the clinic and moving rapidly toward completion of clinical studies and market launch, while the Connect-GJ for endoscopically bypassing malignancy-associated obstruction at the stomach outlet in pancreatic cancer is rapidly approaching initiation of clinical studies.